Related Experiment Video
Updated: Jul 8, 2026
A Unified Methodological Framework for Vestibular Schwannoma Research
Published on: June 20, 2017
ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy
Joni K Doherty1, Weg Ongkeko, Brianna Crawley
1Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California, San Diego, USA. jkdoherty@ucsd.edu
Objective:
Identify molecular targets for development of tumor-specific pharmacotherapeutics aimed at treating vestibular schwannomas (VSs). Activated epidermal growth factor receptor B (ErbB) 2 and ErbB3 are abundantly expressed in VS. ErbB2 signaling is essential for Schwann cell differentiation, survival, and proliferation. VS arise after loss of functional merlin, a putative tumor suppressor. Merlin internalizes ErbB2 receptors in rodent Schwann cells. Unregulated ErbB signaling may contribute to VS tumorigenesis.
Study Design:
Molecular analyses, retrospective clinical correlation.
Setting:
Tertiary referral center.
Patients:
Thirty-eight specimens from patients operated for sporadic (n=21) and neurofibromatosis (NF) 2-related (n=17) VS.
Intervention(S):
VS analyses via real-time polymerase chain reaction, immunohistochemistry, and correlation with patient clinical data.
Main Outcome Measure(S):
ErbB signaling molecule expression, tumor size, age, and NF2 status.
Results:
VS upregulated epidermal growth factor (EGF) receptor in 68% (62% sporadic and 75% NF2-associated VS) and ErbB2 in 84% (76% sporadic and 94% NF2-related VS). ErbB3 was upregulated in 34%, and ErbB4 is downregulated in NF2-related VS. Of EGF receptor (EGFR) ligands, EGF was upregulated in all NF2-related VS, but none of the sporadic VS (p<0.01), and transforming growth factor alpha and beta-cellulin showed upregulation in 67% of NF2-related VS but not sporadic VS (p=0.02 and p=0.01, respectively). Neuregulin (Nrg) was upregulated in 86% of sporadic VS versus 19% of NF2-related VS (p<0.01). EGFR expression levels correlated directly with VS tumor size and inversely with patient age, whereas Nrg expression correlated directly with age (p=0.0005). EGF expression predicts NF2 status, whereas Nrg predicts non-NF2 status (p<0.01).
Conclusion:
These findings implicate the ErbB pathway in VS growth and as potential molecular targets for VS pharmacotherapy.
Insights
The epidermal growth factor receptor (EGFR) pathway is implicated in vestibular schwannoma (VS) growth. Targeting this pathway offers potential for novel VS pharmacotherapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Vestibular schwannomas (VSs) are tumors that arise from Schwann cells.
- Dysregulation of the epidermal growth factor receptor (EGFR) pathway, particularly ErbB2 and ErbB3, is observed in VS.
- Loss of the tumor suppressor merlin is linked to VS development and may affect EGFR signaling.
Purpose of the Study:
- To identify molecular targets for developing tumor-specific pharmacotherapeutics for vestibular schwannomas.
- To investigate the role of the EGFR/ErbB pathway in VS tumorigenesis.
Main Methods:
- Molecular analyses of 38 VS specimens (sporadic and NF2-related) using real-time PCR and immunohistochemistry.
- Retrospective correlation of molecular findings with clinical data, including tumor size, patient age, and NF2 status.
Main Results:
- Upregulation of EGFR (68%) and ErbB2 (84%) was common in VS.
- Differential expression of EGFR ligands (EGF, TGF-α, betacellulin, Nrg) was observed between sporadic and NF2-related VS.
- EGFR expression correlated with tumor size and inversely with age, while Neuregulin correlated with age and predicted non-NF2 status.
Conclusions:
- The ErbB pathway plays a significant role in the growth of vestibular schwannomas.
- EGFR and its ligands represent potential molecular targets for developing targeted therapies against VS.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...